piracetam has been researched along with Benign Neoplasms, Brain in 68 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed a case series analysis to evaluate the effects of levetiracetam (LEV) monotherapy on seizures, adverse events, cognitive functioning and quality of life (QoL) in patients with brain tumor-related epilepsy (BTRE)." | 9.15 | Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. ( Dinapoli, L; Fabi, A; Maschio, M; Muti, P; Pace, A; Sperati, F; Vidiri, A, 2011) |
| "Seizures are common in patients with gliomas, and phenytoin (PHT) is frequently used to control tumor-related seizures." | 9.14 | Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. ( Barbaro, N; Burt, M; Chakalian, L; Chang, E; Chang, S; Lamborn, KR; Lim, DA; McDermott, MW; Tarapore, P, 2009) |
| "To determine the safety and tolerability of IV and oral levetiracetam monotherapy for seizures in brain tumor patients following resection." | 8.86 | A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. ( Finch, CK; Michael, LM; Sills, AK; Usery, JB, 2010) |
| "To confirm the hypothesis suggested above, a combined analysis of survival association of antiepileptic drug use at the start of chemoradiotherapy with temozolomide was performed in the pooled patient cohort (n = 1,869) of four contemporary randomized clinical trials in newly diagnosed glioblastoma: AVAGlio (Avastin in Glioblastoma; NCT00943826), CENTRIC (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status; NCT00689221), CORE (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status; NCT00813943), and Radiation Therapy Oncology Group 0825 (NCT00884741)." | 7.83 | Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. ( Chinot, O; Cloughesy, T; Gilbert, MR; Gorlia, T; Happold, C; Hegi, M; Mehta, MP; Nabors, LB; Perry, JR; Pugh, SL; Reardon, DA; Roth, P; Stupp, R; Weller, M; Wick, W, 2016) |
| "LEV may provide a survival benefit in patients with glioblastoma who receive temozolomide-based chemotherapy." | 7.81 | Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme. ( Han, JH; Joo, JD; Kim, CY; Kim, IA; Kim, T; Kim, YH; Kim, YJ; Yun, CH, 2015) |
| "We report a case of neutropenia related to the use of levetiracetam at first exposure." | 7.81 | Neutropenia secondary to exposure to levetiracetam. ( Boza, FM; Gumà I Padró, J; Peralta Muñoz, S; Taberner Bonastre, MT, 2015) |
| "To examine the efficacy of valproic acid (VPA) given either with or without levetiracetam (LEV) on seizure control and on survival in patients with glioblastoma multiforme (GBM) treated with chemoradiation." | 7.79 | Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. ( Dielemans, JC; Kerkhof, M; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2013) |
| "An open pilot study to evaluate the effect of pregabalin (PGB) as add-on therapy on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy (BTRE)." | 7.78 | Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study. ( Carapella, CM; Dinapoli, L; Fabi, A; Maschio, M; Pace, A; Pompili, A; Sperati, F; Vidiri, A, 2012) |
| " Approximately 30-40% of brain tumors patients who present with status epilepticus (SE) will not respond to typical therapy consisting of benzodiazepines and phenytoin (PHT), resulting in patients with refractory status epilepticus (RSE)." | 7.78 | Phenytoin, levetiracetam, and pregabalin in the acute management of refractory status epilepticus in patients with brain tumors. ( Doreswamy, M; Gingrich, KJ; Kolls, BJ; Swisher, CB; Vredenburgh, JJ, 2012) |
| "To correlate SV2A expression in surgically removed tumor and peritumoral tissue of glioma patients with epilepsy with the clinical response to levetiracetam in a prospective cohort." | 7.77 | Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma. ( Aronica, E; de Groot, M; Heimans, JJ; Reijneveld, JC, 2011) |
| "Rare cases of levetiracetam-induced thrombocytopenia have been reported in the literature." | 7.76 | A case of levetiracetam-induced thrombocytopenia. ( Koubeissi, M; Nock, C; Oghlakian, R, 2010) |
| "To evaluate the efficacy and safety of levetiracetam in the management of epilepsy in patients with glioma." | 7.76 | Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study. ( Buttolo, L; Cenzato, M; Padovani, A; Rosati, A; Stefini, R; Todeschini, A, 2010) |
| "The aim of this pilot study was to investigate the effects of levetiracetam monotherapy on seizure control, quality of life and neurocognitive performance in patients with brain tumor-related epilepsy." | 7.75 | Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study. ( Dinapoli, L; Fabi, A; Jandolo, B; Maschio, M; Muti, P; Pace, A; Sperati, F, 2009) |
| "Levetiracetam (LEV) is a newer anticonvulsant with a favorable safety profile." | 6.77 | Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial. ( Bähr, O; Franz, K; Hermisson, M; Körtvelyessy, P; Nussbaum, S; Rieger, J; Rona, S; Seifert, V; Steinbach, JP; Tatagiba, M; Weller, M, 2012) |
| "Epilepsy is a common clinical problem in patients with brain tumours, strongly affecting patients' quality of life." | 6.72 | Levetiracetam therapy in patients with brain tumour and epilepsy. ( Albani, F; Baruzzi, A; Carapella, CM; Dinapoli, L; Jandolo, B; Maschio, M; Occhipinti, E; Pace, A; Pompili, A; Zarabla, A, 2006) |
| "Nine patients had simple partial seizures, eight had complex partial seizures, and eight had secondary generalized seizures." | 5.46 | Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group. ( Fabi, A; Giannarelli, D; Maialetti, A; Maschio, M; Vidiri, A; Villani, V; Zarabla, A, 2017) |
| "Initial seizure control with enteral levetiracetam was achieved, and when enteral and intravenous (i." | 5.43 | Continuous subcutaneous levetiracetam in the management of seizures at the end of life: a case report. ( Chambers, J; Foreman, E; Mason, LD; Wells, GH, 2016) |
| "Patients with grade IV astrocytoma or glioblastoma multiforme (GBM) have a median survival of <12 months, increased to 14." | 5.43 | Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam. ( Ajit, NE; Burton, GV; El-Osta, H; Peddi, P, 2016) |
| " Haematological toxicity is a limiting side effect of both, first line radio-chemotherapy with temozolomide (TMZ) and co-medication with antiepileptic drugs." | 5.42 | Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study. ( Geroldinger, A; Gleiss, A; Grisold, W; Marosi, C; Moser, W; Oberndorfer, S; Sax, C; Sherif, C; Tinchon, A, 2015) |
| "The postoperative seizure control rates of levetiracetam and valproic acid were not statistically significantly different; however, levetiracetam may be superior to valproic acid in terms of its safety and durability after supratentorial tumor surgery." | 5.39 | Levetiracetam compared with valproic acid for the prevention of postoperative seizures after supratentorial tumor surgery: a retrospective chart review. ( Bae, SH; Han, JH; Kim, CY; Kim, T; Kim, YH; Lee, YJ; Yun, CH, 2013) |
| "To compare the incidence of seizures in patients receiving either prophylactic PHT or LEV perioperatively, 971 patients undergoing a craniotomy were analysed retrospectively during a 2-year period." | 5.38 | Levetiracetam compared to phenytoin for the prevention of postoperative seizures after craniotomy for intracranial tumours in patients without epilepsy. ( Brawanski, AT; Feigl, GC; Hansen, E; Kern, K; Lange, M; Schebesch, KM; Schlaier, J, 2012) |
| "We studied 23 patients with cancer and seizures treated with levetiracetam." | 5.35 | Levetiracetam for seizures in children with brain tumors and other cancers. ( Fisher, PG; Partap, S, 2009) |
| "We performed a case series analysis to evaluate the effects of levetiracetam (LEV) monotherapy on seizures, adverse events, cognitive functioning and quality of life (QoL) in patients with brain tumor-related epilepsy (BTRE)." | 5.15 | Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. ( Dinapoli, L; Fabi, A; Maschio, M; Muti, P; Pace, A; Sperati, F; Vidiri, A, 2011) |
| "Seizures are common in patients with gliomas, and phenytoin (PHT) is frequently used to control tumor-related seizures." | 5.14 | Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. ( Barbaro, N; Burt, M; Chakalian, L; Chang, E; Chang, S; Lamborn, KR; Lim, DA; McDermott, MW; Tarapore, P, 2009) |
| "To determine the safety and tolerability of IV and oral levetiracetam monotherapy for seizures in brain tumor patients following resection." | 4.86 | A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. ( Finch, CK; Michael, LM; Sills, AK; Usery, JB, 2010) |
| "Temozolomide (TMZ) is an alkylating agent used for treatment of brain neoplasms and levetiracetam (LEV) is a commonly used antiepileptic." | 3.85 | Acute liver injury induced by levetiracetam and temozolomide co-treatment. ( Abu Rmeileh, A; Benson, AA; Chen, S; Cohen, J; Daher, S; Khoury, T; Mizrahi, M; Yaari, S, 2017) |
| "To confirm the hypothesis suggested above, a combined analysis of survival association of antiepileptic drug use at the start of chemoradiotherapy with temozolomide was performed in the pooled patient cohort (n = 1,869) of four contemporary randomized clinical trials in newly diagnosed glioblastoma: AVAGlio (Avastin in Glioblastoma; NCT00943826), CENTRIC (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status; NCT00689221), CORE (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status; NCT00813943), and Radiation Therapy Oncology Group 0825 (NCT00884741)." | 3.83 | Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. ( Chinot, O; Cloughesy, T; Gilbert, MR; Gorlia, T; Happold, C; Hegi, M; Mehta, MP; Nabors, LB; Perry, JR; Pugh, SL; Reardon, DA; Roth, P; Stupp, R; Weller, M; Wick, W, 2016) |
| "We report the case of an aborted awake craniotomy for a left frontotemporoinsular glioma due to ammonia encephalopathy on a patient taking Levetiracetam, valproic acid and clobazam." | 3.81 | Ammonia encephalopathy and awake craniotomy for brain language mapping: cause of failed awake craniotomy. ( Arroyo Pérez, R; Fernández-Candil, JL; León Jorba, A; Pacreu Terradas, S; Villalba Martínez, G; Vivanco-Hidalgo, RM, 2015) |
| "LEV may provide a survival benefit in patients with glioblastoma who receive temozolomide-based chemotherapy." | 3.81 | Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme. ( Han, JH; Joo, JD; Kim, CY; Kim, IA; Kim, T; Kim, YH; Kim, YJ; Yun, CH, 2015) |
| "We report a case of neutropenia related to the use of levetiracetam at first exposure." | 3.81 | Neutropenia secondary to exposure to levetiracetam. ( Boza, FM; Gumà I Padró, J; Peralta Muñoz, S; Taberner Bonastre, MT, 2015) |
| "To examine the efficacy of valproic acid (VPA) given either with or without levetiracetam (LEV) on seizure control and on survival in patients with glioblastoma multiforme (GBM) treated with chemoradiation." | 3.79 | Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. ( Dielemans, JC; Kerkhof, M; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2013) |
| " Approximately 30-40% of brain tumors patients who present with status epilepticus (SE) will not respond to typical therapy consisting of benzodiazepines and phenytoin (PHT), resulting in patients with refractory status epilepticus (RSE)." | 3.78 | Phenytoin, levetiracetam, and pregabalin in the acute management of refractory status epilepticus in patients with brain tumors. ( Doreswamy, M; Gingrich, KJ; Kolls, BJ; Swisher, CB; Vredenburgh, JJ, 2012) |
| "An open pilot study to evaluate the effect of pregabalin (PGB) as add-on therapy on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy (BTRE)." | 3.78 | Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study. ( Carapella, CM; Dinapoli, L; Fabi, A; Maschio, M; Pace, A; Pompili, A; Sperati, F; Vidiri, A, 2012) |
| "To correlate SV2A expression in surgically removed tumor and peritumoral tissue of glioma patients with epilepsy with the clinical response to levetiracetam in a prospective cohort." | 3.77 | Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma. ( Aronica, E; de Groot, M; Heimans, JJ; Reijneveld, JC, 2011) |
| "Rare cases of levetiracetam-induced thrombocytopenia have been reported in the literature." | 3.76 | A case of levetiracetam-induced thrombocytopenia. ( Koubeissi, M; Nock, C; Oghlakian, R, 2010) |
| "To evaluate the efficacy and safety of levetiracetam in the management of epilepsy in patients with glioma." | 3.76 | Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study. ( Buttolo, L; Cenzato, M; Padovani, A; Rosati, A; Stefini, R; Todeschini, A, 2010) |
| "The aim of this pilot study was to investigate the effects of levetiracetam monotherapy on seizure control, quality of life and neurocognitive performance in patients with brain tumor-related epilepsy." | 3.75 | Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study. ( Dinapoli, L; Fabi, A; Jandolo, B; Maschio, M; Muti, P; Pace, A; Sperati, F, 2009) |
| "Phenytoin (PHT) is routinely used for seizure prophylaxis in patients with brain tumours during and after craniotomy, despite incomplete evidence." | 2.80 | Levetiracetam versus phenytoin for seizure prophylaxis during and early after craniotomy for brain tumours: a phase II prospective, randomised study. ( Hasegawa, Y; Iuchi, T; Kawasaki, K; Kuwabara, K; Matsumoto, M; Sakaida, T, 2015) |
| "In patients with brain tumors, the choice of antiepileptic medication is guided by tolerability and pharmacokinetic interactions." | 2.79 | Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. ( Jeckelmann, S; Novy, J; Rossetti, AO; Roth, P; Stupp, R; Weller, M, 2014) |
| "Levetiracetam (LEV) is a newer anticonvulsant with a favorable safety profile." | 2.77 | Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial. ( Bähr, O; Franz, K; Hermisson, M; Körtvelyessy, P; Nussbaum, S; Rieger, J; Rona, S; Seifert, V; Steinbach, JP; Tatagiba, M; Weller, M, 2012) |
| "Epilepsy is a common clinical problem in patients with brain tumours, strongly affecting patients' quality of life." | 2.72 | Levetiracetam therapy in patients with brain tumour and epilepsy. ( Albani, F; Baruzzi, A; Carapella, CM; Dinapoli, L; Jandolo, B; Maschio, M; Occhipinti, E; Pace, A; Pompili, A; Zarabla, A, 2006) |
| "Since surgery is believed to aggravate cerebral hypoxia and the consequent neurological dysfunction, patients undergoing surgery for brain tumours or ruptured cerebral aneurysms were studied." | 2.64 | Effect of piracetam on level of consciousness after neurosurgery. ( Bereen, FJ; Richardson, AE, 1977) |
| "SMART syndrome is a delayed complication of brain radiation characterized by neurologic symptoms including migraine-like headaches, seizures, and hemispheric impairment." | 2.55 | Stroke-like migraine attacks after radiation therapy syndrome: Case report and review of the literature. ( Altmeyer, WB; Moise, AM; Singh, AK; Tantiwongkosi, B, 2017) |
| "The tumor, a grade 3 anaplastic oligodendroglioma, was excised, and chemoradiotherapy was administered." | 2.55 | Regression of Recurrent High-Grade Glioma with Temozolomide, Dexamethasone, and Levetiracetam: Case Report and Review of the Literature. ( Abraham Koshy, A; Kumar A, A, 2017) |
| "Studies were included if they reported seizure frequency data pertaining to levetiracetam use in patients with brain tumors as either monotherapy or as an add on agent." | 2.53 | Levetiracetam for seizure prevention in brain tumor patients: a systematic review. ( Nasr, ZG; Paravattil, B; Wilby, KJ, 2016) |
| "The use of AEDs for purposes other than seizure prophylaxis and their selection based on non-PK properties present a potential paradigm shift in the field of neuro-oncology." | 2.53 | Antiepileptic drugs in patients with malignant brain tumor: beyond seizures and pharmacokinetics. ( Gefroh-Grimes, HA; Gidal, BE, 2016) |
| "In most cases, either the seizure or the medications used to treat the seizure may contribute to cognitive and psychosocial difficulties of various degrees of severity." | 2.52 | Clinical Management of Seizures in Patients With Low-Grade Glioma. ( Blakeley, J; Piotrowski, AF, 2015) |
| "Patients with brain tumors remain at risk for infections from the perioperative period through many months after treatment, and steroids may mask signs of infection." | 2.52 | Medical management of patients with brain tumors. ( Pruitt, AA, 2015) |
| "Seizures are a common symptom of brain tumours." | 2.47 | Antiepileptic drugs for treating seizures in adults with brain tumours. ( Grant, R; Kerrigan, S, 2011) |
| "Epileptic seizures are a common clinical problem in children with brain tumors." | 2.46 | Interactions between antiepileptic and chemotherapeutic drugs in children with brain tumors: is it time to change treatment? ( Attinà, G; Battaglia, D; Mastrangelo, S; Riccardi, R; Rizzo, D; Ruggiero, A, 2010) |
| "Therefore, the optimal seizure management by antiepileptic drugs (AEDs) in this patient category is essentially unsure." | 2.43 | Optimal seizure management in brain tumor patients. ( van Breemen, MS; Vecht, CJ, 2005) |
| "Nine patients had simple partial seizures, eight had complex partial seizures, and eight had secondary generalized seizures." | 1.46 | Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group. ( Fabi, A; Giannarelli, D; Maialetti, A; Maschio, M; Vidiri, A; Villani, V; Zarabla, A, 2017) |
| " Psychiatric symptoms occurring after initiation of AED therapy were considered as treatment emergent psychiatric adverse events (TE-PAEs) if they fulfilled the following conditions: (1) onset within 4 weeks after the beginning of AED therapy; (2) disappearance on drug discontinuation; (3) absence of any other identified possible concurrent cause." | 1.46 | Brain tumor location influences the onset of acute psychiatric adverse events of levetiracetam therapy: an observational study. ( Belcastro, V; Bellocchi, S; Casiraghi, P; Gorgone, G; Mula, M; Pisani, F; Pisani, LR, 2017) |
| " Evaluating non-neurobehavioural adverse events of AEDs, no significant differences were found among AEDs, although patients treated with old AEDs had a higher prevalence of adverse events than those treated with new AEDs." | 1.46 | Neuropsychiatric adverse events of antiepileptic drugs in brain tumour-related epilepsy: an Italian multicentre prospective observational study. ( Bedetti, C; Calabresi, P; Costa, C; Di Bonaventura, C; Dispenza, S; Eusebi, P; Maschio, M; Nardi Cesarini, E; Romoli, M; Siliquini, S, 2017) |
| "Patients with grade IV astrocytoma or glioblastoma multiforme (GBM) have a median survival of <12 months, increased to 14." | 1.43 | Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam. ( Ajit, NE; Burton, GV; El-Osta, H; Peddi, P, 2016) |
| "Initial seizure control with enteral levetiracetam was achieved, and when enteral and intravenous (i." | 1.43 | Continuous subcutaneous levetiracetam in the management of seizures at the end of life: a case report. ( Chambers, J; Foreman, E; Mason, LD; Wells, GH, 2016) |
| " Haematological toxicity is a limiting side effect of both, first line radio-chemotherapy with temozolomide (TMZ) and co-medication with antiepileptic drugs." | 1.42 | Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study. ( Geroldinger, A; Gleiss, A; Grisold, W; Marosi, C; Moser, W; Oberndorfer, S; Sax, C; Sherif, C; Tinchon, A, 2015) |
| "Levetiracetam was very well tolerated." | 1.42 | Epilepsy in patients with gliomas: incidence and control of seizures. ( Hasegawa, Y; Iuchi, T; Kawasaki, K; Sakaida, T, 2015) |
| "The postoperative seizure control rates of levetiracetam and valproic acid were not statistically significantly different; however, levetiracetam may be superior to valproic acid in terms of its safety and durability after supratentorial tumor surgery." | 1.39 | Levetiracetam compared with valproic acid for the prevention of postoperative seizures after supratentorial tumor surgery: a retrospective chart review. ( Bae, SH; Han, JH; Kim, CY; Kim, T; Kim, YH; Lee, YJ; Yun, CH, 2013) |
| "53." | 1.39 | Considerations in prophylaxis for tumor-associated epilepsy: prevention of status epilepticus and tolerability of newer generation AEDs. ( Buniak, L; Henry, JC; Mohile, N; Wang, H; Wychowski, T, 2013) |
| "To compare the incidence of seizures in patients receiving either prophylactic PHT or LEV perioperatively, 971 patients undergoing a craniotomy were analysed retrospectively during a 2-year period." | 1.38 | Levetiracetam compared to phenytoin for the prevention of postoperative seizures after craniotomy for intracranial tumours in patients without epilepsy. ( Brawanski, AT; Feigl, GC; Hansen, E; Kern, K; Lange, M; Schebesch, KM; Schlaier, J, 2012) |
| "Breakthrough seizure activity has been reported with conversion from brand name to generic anticonvulsants." | 1.36 | Seizure risk in brain tumor patients with conversion to generic levetiracetam. ( Armstrong, TS; Choi, S; Gilbert, MR; Walker, J, 2010) |
| "Although seizures in brain tumor patients are common, the knowledge on optimal anti-seizure therapy in this patient group is limited." | 1.35 | Efficacy of anti-epileptic drugs in patients with gliomas and seizures. ( Rijsman, RM; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2009) |
| "Almost all (94%) had supratentorial tumors, of which 78% were glial tumors." | 1.35 | The use of antiepileptic drugs in pediatric brain tumor patients. ( Kan, L; Levy, AS; Maytal, J; Shinnar, S; Sogawa, Y, 2009) |
| "We studied 23 patients with cancer and seizures treated with levetiracetam." | 1.35 | Levetiracetam for seizures in children with brain tumors and other cancers. ( Fisher, PG; Partap, S, 2009) |
| "Levetiracetam (LEV) is a 2nd generation non-enzyme inducing AED with a novel mechanism of action, binding to neuronal synaptic vesicle protein SV2A, that has been previously shown to reduce seizure activity in patients with primary brain tumors." | 1.34 | Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors. ( Dalton, J; Goldlust, S; Newton, HB; Pearl, D, 2007) |
| "Older patients and patients with brain tumors or strokes were preferentially treated with LEV for prevention and/or management of seizures (all P < or = 0." | 1.34 | Levetiracetam use in critically ill patients. ( Meckler, JM; Privitera, MD; Shutter, LA; Szaflarski, JP; Szaflarski, M; Yates, SL, 2007) |
| "Seizures are a common complication of primary (PBT) and metastatic (MBT) brain tumors, affecting approximately 50% of all patients during the course of their illness." | 1.33 | Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. ( Goldlust, SA; Newton, HB; Pearl, D, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (4.41) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (23.53) | 29.6817 |
| 2010's | 48 (70.59) | 24.3611 |
| 2020's | 1 (1.47) | 2.80 |
| Authors | Studies |
|---|---|
| Konrath, E | 1 |
| Marhold, F | 1 |
| Kindler, W | 1 |
| Scheichel, F | 1 |
| Popadic, B | 1 |
| Blauensteiner, K | 1 |
| Calabek, B | 1 |
| Freydl, E | 1 |
| Weber, M | 1 |
| Ristl, R | 1 |
| Hainz, K | 1 |
| Sherif, C | 2 |
| Oberndorfer, S | 2 |
| Belcastro, V | 1 |
| Pisani, LR | 1 |
| Bellocchi, S | 1 |
| Casiraghi, P | 1 |
| Gorgone, G | 1 |
| Mula, M | 1 |
| Pisani, F | 1 |
| Tountopoulou, M | 1 |
| Weschke, B | 1 |
| Kaindl, AM | 1 |
| Maschio, M | 7 |
| Zarabla, A | 2 |
| Maialetti, A | 1 |
| Fabi, A | 4 |
| Vidiri, A | 3 |
| Villani, V | 1 |
| Giannarelli, D | 1 |
| Singh, AK | 1 |
| Tantiwongkosi, B | 1 |
| Moise, AM | 1 |
| Altmeyer, WB | 1 |
| Bedetti, C | 1 |
| Romoli, M | 1 |
| Di Bonaventura, C | 1 |
| Nardi Cesarini, E | 1 |
| Eusebi, P | 1 |
| Siliquini, S | 1 |
| Dispenza, S | 1 |
| Calabresi, P | 1 |
| Costa, C | 1 |
| Kumar A, A | 1 |
| Abraham Koshy, A | 1 |
| Feyissa, AM | 1 |
| López-Saca, JM | 1 |
| Vaquero, J | 1 |
| Larumbe, A | 1 |
| Urdíroz, J | 1 |
| Centeno, C | 1 |
| Kerkhof, M | 1 |
| Dielemans, JC | 1 |
| van Breemen, MS | 3 |
| Zwinkels, H | 2 |
| Walchenbach, R | 2 |
| Taphoorn, MJ | 2 |
| Vecht, CJ | 3 |
| Weller, M | 4 |
| Lee, YJ | 1 |
| Kim, T | 2 |
| Bae, SH | 1 |
| Kim, YH | 2 |
| Han, JH | 2 |
| Yun, CH | 2 |
| Kim, CY | 2 |
| Wychowski, T | 1 |
| Wang, H | 1 |
| Buniak, L | 1 |
| Henry, JC | 1 |
| Mohile, N | 1 |
| Rossetti, AO | 2 |
| Jeckelmann, S | 1 |
| Novy, J | 2 |
| Roth, P | 2 |
| Stupp, R | 2 |
| Iuchi, T | 2 |
| Hasegawa, Y | 2 |
| Kawasaki, K | 2 |
| Sakaida, T | 2 |
| Tinchon, A | 1 |
| Marosi, C | 1 |
| Gleiss, A | 1 |
| Geroldinger, A | 1 |
| Sax, C | 1 |
| Moser, W | 1 |
| Grisold, W | 1 |
| Villalba Martínez, G | 1 |
| Fernández-Candil, JL | 1 |
| Vivanco-Hidalgo, RM | 1 |
| Pacreu Terradas, S | 1 |
| León Jorba, A | 1 |
| Arroyo Pérez, R | 1 |
| Kuwabara, K | 1 |
| Matsumoto, M | 1 |
| Simpao, AF | 1 |
| Janik, LS | 1 |
| Hsu, G | 1 |
| Schwartz, AJ | 1 |
| Heuer, GG | 1 |
| Warrington, AP | 1 |
| Rehman, MA | 1 |
| Pruitt, AA | 1 |
| Joo, JD | 1 |
| Kim, YJ | 1 |
| Kim, IA | 1 |
| Gefroh-Grimes, HA | 1 |
| Gidal, BE | 1 |
| Taberner Bonastre, MT | 1 |
| Peralta Muñoz, S | 1 |
| Boza, FM | 1 |
| Gumà I Padró, J | 1 |
| Piotrowski, AF | 1 |
| Blakeley, J | 1 |
| Hatanpaa, KJ | 1 |
| Fuda, F | 1 |
| Koduru, P | 1 |
| Young, K | 1 |
| Lega, B | 1 |
| Chen, W | 1 |
| Wells, GH | 1 |
| Mason, LD | 1 |
| Foreman, E | 1 |
| Chambers, J | 1 |
| Happold, C | 1 |
| Gorlia, T | 1 |
| Chinot, O | 1 |
| Gilbert, MR | 2 |
| Nabors, LB | 1 |
| Wick, W | 1 |
| Pugh, SL | 1 |
| Hegi, M | 1 |
| Cloughesy, T | 1 |
| Reardon, DA | 1 |
| Perry, JR | 1 |
| Mehta, MP | 1 |
| Sonis, J | 1 |
| Borczuk, P | 1 |
| Ptak, T | 1 |
| Miller, ES | 1 |
| Nasr, ZG | 1 |
| Paravattil, B | 1 |
| Wilby, KJ | 1 |
| Habets, JGV | 1 |
| Leentjens, AFG | 1 |
| Schijns, OEMG | 1 |
| Peddi, P | 1 |
| Ajit, NE | 1 |
| Burton, GV | 1 |
| El-Osta, H | 1 |
| Khoury, T | 1 |
| Chen, S | 1 |
| Abu Rmeileh, A | 1 |
| Daher, S | 1 |
| Yaari, S | 1 |
| Benson, AA | 1 |
| Cohen, J | 1 |
| Mizrahi, M | 1 |
| Lee, JW | 2 |
| Bromfield, E | 1 |
| Kesari, S | 3 |
| Partap, S | 1 |
| Fisher, PG | 1 |
| Bromfield, EB | 1 |
| Shershever, AS | 1 |
| Bentsion, DL | 1 |
| Lavrova, SA | 1 |
| Sorokova, EV | 1 |
| Carota, A | 1 |
| Lim, DA | 1 |
| Tarapore, P | 1 |
| Chang, E | 1 |
| Burt, M | 1 |
| Chakalian, L | 1 |
| Barbaro, N | 1 |
| Chang, S | 1 |
| Lamborn, KR | 1 |
| McDermott, MW | 1 |
| Dinapoli, L | 5 |
| Jandolo, B | 3 |
| Pace, A | 4 |
| Sperati, F | 3 |
| Muti, P | 2 |
| Rijsman, RM | 1 |
| Sogawa, Y | 1 |
| Kan, L | 1 |
| Levy, AS | 1 |
| Maytal, J | 1 |
| Shinnar, S | 1 |
| Ruggiero, A | 1 |
| Rizzo, D | 1 |
| Mastrangelo, S | 1 |
| Battaglia, D | 1 |
| Attinà, G | 1 |
| Riccardi, R | 1 |
| Eggers, C | 1 |
| Burghaus, L | 1 |
| Fink, GR | 1 |
| Dohmen, C | 1 |
| Armstrong, TS | 1 |
| Choi, S | 1 |
| Walker, J | 1 |
| Usery, JB | 1 |
| Michael, LM | 1 |
| Sills, AK | 1 |
| Finch, CK | 1 |
| Rosati, A | 1 |
| Buttolo, L | 1 |
| Stefini, R | 1 |
| Todeschini, A | 1 |
| Cenzato, M | 1 |
| Padovani, A | 1 |
| Oghlakian, R | 1 |
| Nock, C | 1 |
| Koubeissi, M | 1 |
| Engh, JA | 1 |
| de Groot, M | 2 |
| Aronica, E | 1 |
| Heimans, JJ | 2 |
| Reijneveld, JC | 2 |
| Kerrigan, S | 1 |
| Grant, R | 1 |
| Swisher, CB | 1 |
| Doreswamy, M | 1 |
| Gingrich, KJ | 1 |
| Vredenburgh, JJ | 1 |
| Kolls, BJ | 1 |
| Bähr, O | 1 |
| Hermisson, M | 1 |
| Rona, S | 1 |
| Rieger, J | 1 |
| Nussbaum, S | 1 |
| Körtvelyessy, P | 1 |
| Franz, K | 1 |
| Tatagiba, M | 1 |
| Seifert, V | 1 |
| Steinbach, JP | 1 |
| Mahta, A | 1 |
| Kim, RY | 1 |
| Kern, K | 1 |
| Schebesch, KM | 1 |
| Schlaier, J | 1 |
| Hansen, E | 1 |
| Feigl, GC | 1 |
| Brawanski, AT | 1 |
| Lange, M | 1 |
| Fisch, L | 1 |
| Mégevand, P | 1 |
| Badoud, S | 1 |
| Badoud, A | 1 |
| Seeck, M | 1 |
| Burkhard, PR | 1 |
| Douw, L | 1 |
| Sizoo, EM | 1 |
| Bosma, I | 1 |
| Froklage, FE | 1 |
| Postma, TJ | 1 |
| Klein, M | 1 |
| Pompili, A | 2 |
| Carapella, CM | 2 |
| Wagner, GL | 1 |
| Wilms, EB | 1 |
| Van Donselaar, CA | 1 |
| Vecht, ChJ | 1 |
| Newton, HB | 2 |
| Goldlust, SA | 1 |
| Pearl, D | 2 |
| Albani, F | 1 |
| Baruzzi, A | 1 |
| Occhipinti, E | 1 |
| Dalton, J | 1 |
| Goldlust, S | 1 |
| Szaflarski, JP | 1 |
| Meckler, JM | 1 |
| Szaflarski, M | 1 |
| Shutter, LA | 1 |
| Privitera, MD | 1 |
| Yates, SL | 1 |
| von Metzler, A | 2 |
| Nitsch, C | 2 |
| Richardson, AE | 1 |
| Bereen, FJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Prospective Trial for Validation of the Role of Levetiracetam as a Sensitizer of Temozolomide in the Treatment of Newly Diagnosed Glioblastoma Patients[NCT02815410] | Phase 2 | 73 participants (Anticipated) | Interventional | 2016-07-31 | Not yet recruiting | ||
| Prospective Trial of Intravenous Levetiracetam in Patients With Primary Brain Tumors and at Least One Symptomatic Seizure Who Undergo Biopsy or Cytoreductive Surgery (HELLO-study)[NCT00571155] | Phase 4 | 30 participants (Anticipated) | Interventional | 2007-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for piracetam and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Stroke-like migraine attacks after radiation therapy syndrome: Case report and review of the literature.
Topics: Adult; Brain Neoplasms; Female; Humans; Levetiracetam; Magnetic Resonance Imaging; Migraine Disorder | 2017 |
Regression of Recurrent High-Grade Glioma with Temozolomide, Dexamethasone, and Levetiracetam: Case Report and Review of the Literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Corpus Ca | 2017 |
Medical management of patients with brain tumors.
Topics: Angiogenesis Inhibitors; Anticonvulsants; Brain Edema; Brain Neoplasms; Cognition Disorders; Dopamin | 2015 |
Antiepileptic drugs in patients with malignant brain tumor: beyond seizures and pharmacokinetics.
Topics: Animals; Anticonvulsants; Brain Neoplasms; Carbamazepine; Humans; Levetiracetam; Piracetam; Seizures | 2016 |
Clinical Management of Seizures in Patients With Low-Grade Glioma.
Topics: Anticonvulsants; Brain Neoplasms; Glioma; Humans; Lamotrigine; Levetiracetam; Piracetam; Seizures; T | 2015 |
Levetiracetam for seizure prevention in brain tumor patients: a systematic review.
Topics: Anticonvulsants; Brain Neoplasms; Humans; Levetiracetam; Observational Studies as Topic; Piracetam; | 2016 |
Interactions between antiepileptic and chemotherapeutic drugs in children with brain tumors: is it time to change treatment?
Topics: Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Child; Child, Preschool; Drug Interactions; | 2010 |
A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures.
Topics: Administration, Oral; Adult; Aged; Anticonvulsants; Brain Neoplasms; Dose-Response Relationship, Dru | 2010 |
Antiepileptic drugs for treating seizures in adults with brain tumours.
Topics: Adult; Anticonvulsants; Brain Neoplasms; Drug Substitution; Humans; Levetiracetam; Phenytoin; Pirace | 2011 |
Optimal seizure management in brain tumor patients.
Topics: Amines; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Cyclohexanecarboxylic Acids; Drug I | 2005 |
7 trials available for piracetam and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study.
Topics: Anticonvulsants; Brain Neoplasms; Epilepsy; Female; Follow-Up Studies; gamma-Aminobutyric Acid; Huma | 2014 |
Levetiracetam versus phenytoin for seizure prophylaxis during and early after craniotomy for brain tumours: a phase II prospective, randomised study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Neoplasms; Cohort Studies; Cranio | 2015 |
Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Neoplasms; Craniotomy; Female; Glioma; Humans | 2009 |
Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life.
Topics: Adult; Aged; Anticonvulsants; Brain Neoplasms; Epilepsy; Female; Follow-Up Studies; Humans; Levetira | 2011 |
Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial.
Topics: Administration, Oral; Adult; Aged; Anticonvulsants; Brain Neoplasms; Chemotherapy, Adjuvant; Electro | 2012 |
Levetiracetam therapy in patients with brain tumour and epilepsy.
Topics: Adult; Aged; Anticonvulsants; Brain Neoplasms; Drug Therapy, Combination; Epilepsy; Female; Humans; | 2006 |
Effect of piracetam on level of consciousness after neurosurgery.
Topics: Brain Neoplasms; Cerebral Cortex; Consciousness; Humans; Hypoxia, Brain; Intracranial Aneurysm; Pira | 1977 |
51 other studies available for piracetam and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Perioperative levetiracetam for seizure prophylaxis in seizure-naive brain tumor patients with focus on neurocognitive functioning.
Topics: Anticonvulsants; Brain Neoplasms; Humans; Levetiracetam; Piracetam; Prospective Studies; Quality of | 2022 |
Brain tumor location influences the onset of acute psychiatric adverse events of levetiracetam therapy: an observational study.
Topics: Aged; Anticonvulsants; Brain Neoplasms; Cohort Studies; Electroencephalography; Epilepsy; Female; Hu | 2017 |
Lacosamide Lowers Valproate and Levetiracetam Levels.
Topics: Acetamides; Adolescent; Anticonvulsants; Brain Neoplasms; Drug Interactions; Epilepsies, Partial; Hu | 2017 |
Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.
Topics: Acetamides; Adult; Affect; Aged; Anticonvulsants; Brain Neoplasms; Drug Therapy, Combination; Epilep | 2017 |
Neuropsychiatric adverse events of antiepileptic drugs in brain tumour-related epilepsy: an Italian multicentre prospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Neoplasms; Epilepsy; Female; Humans; Italy; L | 2017 |
Antiepileptic drug-related neuropsychiatric adverse events in brain tumor-related epilepsy: levetiracetam front and center.
Topics: Anticonvulsants; Brain Neoplasms; Epilepsy; Humans; Levetiracetam; Piracetam | 2017 |
Repeated use of subcutaneous levetiracetam in a palliative care patient.
Topics: Aged; Anticonvulsants; Brain Neoplasms; Dose-Response Relationship, Drug; Epilepsy; Female; Humans; | 2013 |
Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2013 |
Are we ready for a randomized trial of valproic acid in newly diagnosed glioblastoma?
Topics: Anticonvulsants; Brain Neoplasms; Female; Glioblastoma; Humans; Levetiracetam; Male; Neoplasm Recurr | 2013 |
Levetiracetam compared with valproic acid for the prevention of postoperative seizures after supratentorial tumor surgery: a retrospective chart review.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Neoplasms; Child; Child, Preschoo | 2013 |
Considerations in prophylaxis for tumor-associated epilepsy: prevention of status epilepticus and tolerability of newer generation AEDs.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Brain Neoplasms; Female; Humans; Levetiracetam; Male; Midd | 2013 |
Epilepsy in patients with gliomas: incidence and control of seizures.
Topics: Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Carbamazepine; Female; Glioma; Humans; Inci | 2015 |
Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study.
Topics: Adult; Aged; Anticonvulsants; Blood Cell Count; Blood Cells; Brain Neoplasms; Chemoradiotherapy; Fem | 2015 |
Ammonia encephalopathy and awake craniotomy for brain language mapping: cause of failed awake craniotomy.
Topics: Anesthesia, General; Anesthesia, Local; Anticonvulsants; Aphasia; Benzodiazepines; Brain Diseases; B | 2015 |
Transient and reproducible loss of motor-evoked potential signals after intravenous levetiracetam in a child undergoing craniotomy for resection of astrocytoma.
Topics: Anticonvulsants; Astrocytoma; Brain Neoplasms; Child; Craniotomy; Evoked Potentials, Motor; Evoked P | 2015 |
Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2015 |
Neutropenia secondary to exposure to levetiracetam.
Topics: Adenocarcinoma; Anticonvulsants; Brain Neoplasms; Craniotomy; Drug Administration Schedule; Humans; | 2015 |
Lymphomatosis Cerebri: A Diagnostic Challenge.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; DNA-Binding Proteins; Female; Frontal Lobe; Humans; Im | 2015 |
Continuous subcutaneous levetiracetam in the management of seizures at the end of life: a case report.
Topics: Aged, 80 and over; Anticonvulsants; Brain Neoplasms; Carcinoma, Squamous Cell; Head and Neck Neoplas | 2016 |
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemor | 2016 |
Seizure and Fever.
Topics: Acyclovir; Adrenal Cortex Hormones; Anti-Bacterial Agents; Antiviral Agents; Brain Neoplasms; Ceftri | 2016 |
Serious and reversible levetiracetam-induced psychiatric symptoms after resection of frontal low-grade glioma: two case histories.
Topics: Anticonvulsants; Brain Neoplasms; Craniotomy; Epilepsy; Frontal Lobe; Humans; Levetiracetam; Magneti | 2017 |
Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cognition Disorders; D | 2016 |
Acute liver injury induced by levetiracetam and temozolomide co-treatment.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studi | 2017 |
Emesis responsive to levetiracetam.
Topics: Aged; Anticonvulsants; Brain Neoplasms; Female; Humans; Levetiracetam; Papilloma, Choroid Plexus; Pi | 2008 |
Levetiracetam for seizures in children with brain tumors and other cancers.
Topics: Adolescent; Anticonvulsants; Brain Neoplasms; Child; Drug Evaluation; Female; Humans; Levetiracetam; | 2009 |
Antiemetic properties of the antiepileptic drug levetiracetam.
Topics: Age Factors; Anticonvulsants; Antiemetics; Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Hum | 2008 |
[Use of keppra during the radiotherapy in patients with brain tumors and epileptic seizures after surgical treatment].
Topics: Administration, Oral; Adolescent; Adult; Anticonvulsants; Brain Neoplasms; Child; Dose-Response Rela | 2008 |
Symptomatic complex partial status epilepticus manifesting as utilization behavior of a mobile phone.
Topics: Anticonvulsants; Benzodiazepines; Brain Neoplasms; Cell Phone; Clobazam; Electroencephalography; Epi | 2009 |
Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study.
Topics: Activities of Daily Living; Adult; Aged; Anticonvulsants; Blood Cell Count; Brain Neoplasms; Combine | 2009 |
Efficacy of anti-epileptic drugs in patients with gliomas and seizures.
Topics: Adult; Anticonvulsants; Brain Neoplasms; Carbamazepine; Drug Therapy, Combination; Female; Follow-Up | 2009 |
The use of antiepileptic drugs in pediatric brain tumor patients.
Topics: Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Carbamazepine; Child; Drug Interactions; Fo | 2009 |
Epilepsia partialis continua responsive to intravenous levetiracetam.
Topics: Anticonvulsants; Brain Neoplasms; Epilepsies, Partial; Female; Humans; Injections, Intravenous; Leve | 2009 |
Seizure risk in brain tumor patients with conversion to generic levetiracetam.
Topics: Adult; Anticonvulsants; Brain Neoplasms; Drugs, Generic; Female; Humans; Levetiracetam; Male; Middle | 2010 |
Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study.
Topics: Adult; Aged; Anticonvulsants; Brain Neoplasms; Dose-Response Relationship, Drug; Epilepsy; Female; G | 2010 |
In reference to Usery JB et al. (J Neuro-oncol. 2010 Feb 10).
Topics: Brain Neoplasms; Humans; Levetiracetam; Nootropic Agents; Piracetam; Prospective Studies | 2010 |
A case of levetiracetam-induced thrombocytopenia.
Topics: Anticonvulsants; Brain Neoplasms; Epilepsies, Partial; Female; Frontal Lobe; Glioblastoma; Humans; L | 2010 |
Anti-convulsants and gene expression in malignant gliomas.
Topics: Brain Neoplasms; Convulsants; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplast | 2010 |
Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma.
Topics: Adult; Aged; Blotting, Western; Brain Neoplasms; Cohort Studies; Epilepsy; False Positive Reactions; | 2011 |
Phenytoin, levetiracetam, and pregabalin in the acute management of refractory status epilepticus in patients with brain tumors.
Topics: Acute Disease; Aged; Anticonvulsants; Brain Neoplasms; Drug Therapy, Combination; Female; gamma-Amin | 2012 |
Levetiracetam-induced interstitial nephritis in a patient with glioma.
Topics: Acute Kidney Injury; Anticonvulsants; Astrocytoma; Brain Neoplasms; Humans; Levetiracetam; Male; Mid | 2012 |
Levetiracetam compared to phenytoin for the prevention of postoperative seizures after craniotomy for intracranial tumours in patients without epilepsy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Child; Contraindications; Craniotomy; F | 2012 |
Pilomotor seizure: when paroxysmal gooseflesh heralds brain tumor.
Topics: Aged; Amygdala; Anticonvulsants; Astrocytoma; Brain Neoplasms; Electroencephalography; Hippocampus; | 2012 |
Levetiracetam improves verbal memory in high-grade glioma patients.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Brain Neoplasms; Cognition Disorders; Female; Glioma; Huma | 2013 |
Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study.
Topics: Adult; Aged; Anticonvulsants; Anxiety; Benzodiazepines; Brain Neoplasms; Carbamazepine; Clobazam; Dr | 2012 |
Levetiracetam: preliminary experience in patients with primary brain tumours.
Topics: Brain Neoplasms; Follow-Up Studies; Glioma; Humans; Levetiracetam; Piracetam; Prospective Studies; S | 2003 |
Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Neoplasms; Female; Humans; Levetiracetam; Mal | 2006 |
Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors.
Topics: Adult; Aged; Anticonvulsants; Brain Neoplasms; Female; Humans; Levetiracetam; Male; Middle Aged; Pir | 2007 |
Levetiracetam use in critically ill patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Diseases; Brain Ne | 2007 |
[Effects of 3-methylcholanthrene and 3-methylcholanthrene plus piracetam on the gamma-amino-butyric acid (GABA) content of several cerebral regions (author's transl)].
Topics: Aminooxyacetic Acid; Animals; Brain Chemistry; Brain Neoplasms; gamma-Aminobutyric Acid; Methylchola | 1981 |
Monoamine content in rat brain during carcinogenesis and the influence of the CNS drugs piracetam and imipramine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Brain Neoplasms; Caudate Nucleus; Female; | 1985 |